Literature DB >> 1576664

Studies on constituents of fruit body of Polyporus umbellatus and their cytotoxic activity.

T Ohsawa1, M Yukawa, C Takao, M Murayama, H Bando.   

Abstract

From the crude drug Chorei, the fruit body of Polyporus umbellatus, seven new components named polyporusterone A, B, C, D, E, F and G, were isolated and their structures were determined on the basis of the spectral data. These compounds showed cytotoxic action on leukemia 1210 cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576664     DOI: 10.1248/cpb.40.143

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  5 in total

1.  Evidence for the involvement of 3-oxo-delta 4 intermediates in ecdysteroid biosynthesis.

Authors:  C Blais; C Dauphin-Villemant; N Kovganko; J P Girault; C Descoins; R Lafont
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

2.  Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid.

Authors:  Jean-San Chia; Jia-Ling Du; Wei-Bin Hsu; Andy Sun; Chun-Pin Chiang; Won-Bo Wang
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

3.  Sclerotial formation of Polyporus umbellatus by low temperature treatment under artificial conditions.

Authors:  Yong-Mei Xing; Li-Chun Zhang; Han-Qiao Liang; Jing Lv; Chao Song; Shun-Xing Guo; Chun-Lan Wang; Tae-Soo Lee; Min-Woong Lee
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Identification of Molecular Targets and Potential Mechanisms of Yinchen Wuling San Against Head and Neck Squamous Cell Carcinoma by Network Pharmacology and Molecular Docking.

Authors:  Biyu Zhang; Genyan Liu; Xin Wang; Xuelei Hu
Journal:  Front Genet       Date:  2022-07-06       Impact factor: 4.772

5.  Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology.

Authors:  Zhulin Wu; Chunshan Wei; Lianan Wang; Li He
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-29       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.